Therapeutic Antibodies – Multimedia

Download this infographic to learn about next generation antibodies, the challenges of traditional technologies for antibody-based discovery and development and innovative solutions that are addressing these challenges

Here we take a look at some of the drugs currently undergoing preclinical and clinical development for COVID-19.

This eBook is packed with technical articles, webinars and solution guides on the characterization of biotherapeutics.

This list outlines the new molecular entities (NMEs) and new therapeutic biological products approved by the FDA’s Center for Drug Evaluation and Research (CDER) during 2019.

This listicle explores the five different types of immunotherapy, how each type works, and takes a closer look at some examples of approved immunotherapies.

Monoclonal antibodies, like the drugs Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxin (rituximab), are effective in treating a wide range of cancer types such as lung cancer, breast cancer, lymphoma, and others. By binding to cancer antigens, monoclonal antibodies mark the cells for destruction by the immune system. Clinical trials of more monoclonal antibodies for additional cancer types are ongoing.

Download this free eBook for articles, webinars and solution guides to help you extend your analytical capabilities, drive lab throughput and streamline your workflows.

In this up-to-date list of milestones in therapeutic antibody engineering, you can learn about the first FDA-approved therapeutic antibody, the discovery of phage display libraries, bispecific antibodies and more.

This list highlights ten major milestones within the field of cancer research since the year 2000.

Antibody–drug conjugates or ADCs represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies (mAbs) with the potent cell killing activity of cytotoxic small molecule drugs.